Forsta AP Fonden boosted its position in shares of Humana Inc. (NYSE:HUM – Free Report) by 10.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,700 shares of the insurance provider’s stock after acquiring an additional 2,900 shares during the period. Forsta AP Fonden’s holdings in Humana were worth $15,389,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in HUM. Cibc World Market Inc. grew its holdings in Humana by 4.0% during the 1st quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock worth $2,484,000 after acquiring an additional 217 shares in the last quarter. Blair William & Co. IL boosted its holdings in shares of Humana by 0.6% in the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock valued at $2,463,000 after buying an additional 32 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Humana by 0.5% in the 1st quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock valued at $2,135,000 after buying an additional 26 shares in the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Humana by 19.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock valued at $268,000 after buying an additional 98 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Humana by 25.0% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock valued at $12,971,000 after buying an additional 5,964 shares in the last quarter. Institutional investors and hedge funds own 93.21% of the company’s stock.
Humana Stock Down 0.2 %
Shares of NYSE HUM opened at $446.27 on Wednesday. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 0.59. Humana Inc. has a 52 week low of $435.00 and a 52 week high of $571.30. The firm has a 50-day moving average price of $496.75 and a 200 day moving average price of $498.86. The stock has a market capitalization of $55.76 billion, a price-to-earnings ratio of 18.13, a price-to-earnings-growth ratio of 1.17 and a beta of 0.67.
Humana (NYSE:HUM – Free Report) last announced its quarterly earnings data on Wednesday, April 26th. The insurance provider reported $9.38 EPS for the quarter, beating the consensus estimate of $9.25 by $0.13. Humana had a net margin of 3.26% and a return on equity of 21.04%. The firm had revenue of $26.74 billion during the quarter, compared to analysts’ expectations of $26.40 billion. During the same quarter last year, the business earned $8.04 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Equities research analysts anticipate that Humana Inc. will post 28.28 EPS for the current fiscal year.
Humana Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Thursday, June 29th. Humana’s dividend payout ratio (DPR) is 14.38%.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on HUM shares. Truist Financial lowered their target price on shares of Humana from $590.00 to $530.00 in a report on Tuesday, June 20th. Argus cut shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. StockNews.com started coverage on shares of Humana in a research report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Cantor Fitzgerald started coverage on shares of Humana in a research report on Thursday, April 20th. They set an “overweight” rating and a $597.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on shares of Humana from $620.00 to $637.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 11th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $600.56.
Insider Activity at Humana
In other Humana news, CFO Susan M. Diamond sold 4,156 shares of Humana stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $526.28, for a total transaction of $2,187,219.68. Following the completion of the transaction, the chief financial officer now owns 3,931 shares in the company, valued at $2,068,806.68. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.32% of the company’s stock.
Humana Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.